Caymus Partners LLC (“Caymus Partners”) is pleased to announce that it has successfully completed a valuation opinion for Zygogen, LLC (“Zygogen” or the “Company”) .

About Zygogen

Zygogen is a privately owned, Atlanta-based biotechnology company founded in 1999 to develop proprietary zebrafish models of human disease for preclinical drug discovery. A pioneer in applying zebrafish technology to drug discovery, Zygogen continues to establish discovery service collaborations with pharmaceutical companies to screen compounds for oncology and Parkinson’s disease as well as validate targets for multiple therapeutic areas.

"The Caymus Partners team was extremely strong and knowledgeable from top to bottom and dedicated significant senior-level resources. Not only did they bring significant financial expertise, but they immediately understood our technology, intellectual property and the marketplace. It was a challenging exercise given the stage of the Company and the lack of comparable companies. However, Caymus Partners analyzed various valuation methodologies across multiple industry sectors in an extremely thorough manner to properly determine a thoughtful and defendable valuation range. I was very impressed with Caymus Partners’ deep understanding of our business and industry, which helped ensure a meaningful valuation."

Nina Sawczuk
Chief Executive Officer

About Caymus Partners